Defining the Name of the Game in Exercise Oncology Authors: Enat Arega, Christina M Dieli-Conwright, Eric H Yang Published: 2025 ABSTRACT Corresponding AuthorKey Words: behavioral risk factors, breast cancer, cancer survivorship, exercise oncology, lifestyle risk factors, prevention Advances in cancer care have improved survival, but a growing population of cancer survivors faces a disproportionate burden of major cardiac adverse events. These risks are not evenly distributed; Black and Hispanic adults experience higher rates of cardiotoxicity and cardiovascular complications, driven by both cardiotoxic effects of cancer-directed therapies and structural inequities that shape baseline health.1 Limited access to preventative care, delayed diagnosis, and higher prevalence of comorbidities such as low physical activity, chronic inflammation, and metabolic syndrome compound vulnerability in these populations. Among these factors, physical activity is highly modifiable; yet, engagement varies by race and ethnicity, with lower mean leisure-time moderate-to-vigorous intensity physical activity observed among Black and non-White Latino adults.2,3 Recently, the impact of physical activity in the cancer population has garnered interest as a possible therapy with a multitude of potential benefits. Exercise is associated with improved cardiovascular fitness, reduced fatigue, and enhanced emotional well-being.4, 5, 6 Higher levels of physical activity also have a prognostic value, with increased physical activity linked to reductions in all-cause and cancer-specific mortality across multiple malignancies.7,8 To support optimal health outcomes, guidelines recommend that individuals engage in at least 150 minutes of moderate-intensity physical activity or 75 minutes of vigorous-intensity physical activity per week.7,9 Nonetheless, many patients do not meet the recommended activity levels, in part because of the behavioral challenges associated with initiating and sustaining physical activity. This has led to a core question: how can cancer survivors be motivated and incentivized to improve physical activity? This issue of JACC: CardioOncology includes results from ALLSTAR (Randomized Controlled Trial of Strategies to Augment Physical Activity in Black and Hispanic Breast and Prostate Cancer Survivors), a randomized clinical trial conducted at 2 tertiary cancer centers in Southern California and southeastern Pennsylvania, focusing on breast and prostate cancer survivors who self-identified as Black or Hispanic.10 Inclusion criteria consisted of having received cardiotoxic therapies, having at least 1 cardiovascular risk factor, owning a smartphone, and demonstrating literacy in either English or Spanish. Participants who had <1,000 or >7,500 steps/day during a run-in period were excluded. The investigators leveraged principles from psychology and behavioral economics to design a clinical trial evaluating if gamification-based interventions can improve physical activity engagement among prostate or breast cancer survivors who identify as Black or non-White Hispanic, populations known to be at an elevated risk for cardiovascular events.1,11 Patients were randomized to an “attention control” arm and to a “gamification” strategy for 24 weeks. The latter group was given a smartphone app game constructed from behavioral economics that had shown increases in physical activity in prior studies.11 By incorporating elements such as points, challenges, rewards, and social support in the gamification arm, participants in this arm experienced a greater change from baseline in mean daily steps during the intervention period (+759; P = 0.007) and follow-up period (+581; P = 0.070). Additionally, the group saw a greater increase in weekly minutes of moderate-vigorous activity during intervention (+16; P = 0.010) and follow-up (+11; P = 0.048). Although this study provides valuable insight into a scalable behavioral intervention, several limitations warrant careful consideration. First, the sample may not be representative of the broader cancer survivor population. Given participants between 1,000 and 7,500 daily step counts were included in the study, it could be surmised that cancer survivors on both ends of the exercise spectrum--from very sedentary to highly active--were not included in this trial. Participants were predominantly higher educated, and recruitment was limited to 2 comprehensive cancer centers, excluding individuals who did not meet the literacy requirements, or who reside in areas outside the catchment area of the 2 centers. This restricts generalizability to populations residing in more rural areas, with lower health literacy, or from linguistically diverse backgrounds. Second, the study design is subject to self-selection bias. Patients who opted into the trial may already be more motivated to increase physical activity than those who decline participation. Additionally, randomization did not fully balance baseline characteristics. Participants assigned to the gamification arm appeared to be of higher socioeconomic status, as suggested by higher education, higher income, and lower Area Deprivation Index scores relative to control subjects. Such differences may correspond to greater access to safe outdoor spaces or recreational facilities, which could independently influence activity levels and confound the intervention effect. The control group also received text message reminders, representing an active comparison rather than a true standard-of-care control. Thus, the intervention’s effect size may be conservative, and the full potential of a gamification-based strategy might be underestimated in this study design. Finally, the specific physical activity intervention itself may not be an effective stimulus to mitigate CVD-related health outcomes. New research suggests that 7,000 daily steps is beneficial for longevity and heart health in a review of 57 studies.11 Compared with people who walked only 2,000 steps/day, those who tracked 7,000 daily steps had a 25% lower risk of cardiovascular disease and a 47% lower risk of all-cause mortality. Thus, although evidence suggests the benefits of increasing daily step count in populations such as cancer survivors exposed to cardiotoxic therapies, certain populations, including Black and Hispanic adults, are less studied in clinical trial settings. Given the multiple risk factors of these populations, it could be argued that more structured, progressive aerobic and resistance exercise programs are warranted. Despite these limitations, there are several notable strengths. As a well-designed randomized controlled trial with adequate power and an intention-to-treat analytic approach, it provides a rigorous assessment of the intervention’s impact on physical activity. The gamification strategy is inherently scalable, is capable of being integrated into digital health platforms, and is adaptable to diverse patient populations. Together, these features demonstrate that even low-cost behavioral interventions can effectively increase physical activity in cancer survivors—a population at substantial risk for adverse cardiovascular outcomes. Findings from this study hold important implications for preventative cardio-oncology. By shifting physical activity from passive recommendation to an interactive, personalized experience, gamification may improve long-term adherence and empower survivors to take ownership of their cardiovascular health. As health systems and insurers increasingly recognize the value of prevention, as evidenced by coverage of gym memberships and wellness programs, digital behavior-change tools represent a logical next step, but reimbursement structures for physical activity have lagged. Current payment models prioritize center-based services while leaving most digital, community-centered, culturally tailored interventions without sustainable funding, risking their adoption only among higher-income individuals and potentially widening existing disparities.6 Funding and integrating gamified, digital physical activity tools into patient portals and then deploying them in multiple languages could expand access to those historically underserved by traditional health promotion strategies.12 If implemented ethically and equitably, gamified interventions offer a path to reducing disparities and reshaping survivorship care through engaging, patient-centered prevention. In conclusion, the authors are to be congratulated in identifying gamification as a low-cost and scalable intervention that may help patients achieve guideline-recommended activity levels. ALLSTAR acts as a complementary study, and an alternative strategy, to the recently published CHALLENGE (Colon Health and Lifelong Exercise Change) trial, which demonstrated a significant decrease in disease-free survival in colorectal cancer survivors who underwent a 3-year supervised exercise program.8 There are many future avenues to explore (Figure 1), but expanding these strategies to larger and more nationally representative samples are needed to ensure the generalizability of these results. Such efforts will hopefully lead to successful strategies in incentivizing physical activity to improve CVD health outcomes in the growing and diverse cancer population and get us closer to defining the “name of the game” in exercise oncology. Future Avenues in Implementing Effective Exercise Programs for the Cancer Population Created by biorender.com. CV = cardiovascular; SES = socioeconomic status. Funding Support and Author Disclosures Dr Yang has received research funding from Amgen, Bristol Myers Squibb, Janssen Research and Development, and Novo Nordisk (all nonrelevant); has received consulting fees from Xencor and Edwards Lifesciences (all nonrelevant); and has received speaker fees from Zoll Medical (nonrelevant). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Footnotes Ronald Witteles, MD, Deputy Editor, served as Acting Editor-in-Chief for this paper. The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center. References